Healthcare Industry News: Stereotaxis
News Release - October 25, 2007
Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation SystemAdvanced 3D Vessel Road Mapping and Magnetic Guidewire Navigation Capabilities Demonstrated in Multiple Cases
ST. LOUIS, Oct. 25 (HSMN NewsFeed) -- Stereotaxis, Inc. (Nasdaq: STXS ) announced today the details of successful, live percutaneous coronary and peripheral cases performed with the Stereotaxis Magnetic Navigation System and broadcast to the Main Arena at the Transcatheter Cardiovascular Therapeutics (TCT) symposium, held this week in Washington D.C. In each of the cases, Stereotaxis technology was used to create a three-dimensional (3D) roadmap of a stenotic or occluded vessel which aided magnetic guidewire crossing of the occlusion or stenosis for successful delivery of the necessary therapy.
-- Coronary Bifurcation Stenosis -- In the first case, a 3D image of the bifurcation was constructed from multiple x-ray images and the images were overlaid on real-time fluoroscopy to create a centerline roadmap through the lesion. Two Stereotaxis magnetic guidewires were efficiently navigated down the stenotic branches of the bifurcation. The guidewires successfully crossed the stenoses and two stents were deployed. This procedure was performed on Monday, October 22 by Dr. Jeff Moses of New York Presbyterian/Columbia University Medical Center.
-- Chronic Total Occlusion -- This second case included the treatment of a coronary chronic total occlusion, or CTO. A 3D roadmap of the fully occluded vessel, based on recently conducted CT studies, was created using the Stereotaxis system. Overlaid onto real-time fluoroscopy, the roadmap enabled guidewire advancement, CTO lesion crossing and therapy delivery. This procedure was also performed by Dr. Moses, on Tuesday, October 23.
-- Subclavian Stenosis -- The third Stereotaxis live case demonstration at TCT, also on Tuesday the 23rd, was performed by Dr. Mark Reisman of the Swedish Heart and Vascular Institute, during which he used the Stereotaxis system to produce a 3D vascular map and successfully cross a subclavian stenosis to permit stent deployment. A prior two-hour conventional percutaneous intervention of this patient was unsuccessful due to extreme vessel tortuosity and larger vessel diameter. However, crossing of the subclavian lesion with a Stereotaxis 3D vessel roadmap and magnetic guidewire tip guidance was accomplished in less than 10 seconds of wiring time.
"The Stereotaxis Magnetic Navigation platform enabled our procedure significantly by facilitating the passage of wires in complex peripheral anatomy," said Dr. Reisman. "This patient benefited by the reduced procedure time and contrast load, and resulted in the minimizing of potential complications to the neurovascular circulation."
"We are very pleased that these three patients were able to receive the treatment they needed, and that all are recovering well," said Bevil Hogg, CEO of Stereotaxis. "Their procedures demonstrate the clinical value of Stereotaxis' 3D vessel roadmaps and distal tip control of magnetic guidewires in the treatment of complex coronary and peripheral vasculature disease. We believe that Stereotaxis' advanced coronary and peripheral navigation capabilities can bring a new level of simplicity, safety and precision to a variety of vascular interventions, and we were proud that leading cardiologists chose to use our technology in live cases at TCT."
At TCT, Stereotaxis showcased the interventional cardiology capabilities of its Stereotaxis Magnetic Navigation System, which include CTO vessel road mapping and image integration, as well as the global connectivity capabilities of its Odyssey(TM) Network Solutions. In the "Cath Lab of the Future," which was sponsored by TCT, the company demonstrated important advances in vascular interventional technology and outlined plans to advance the therapeutic care of patients in the areas of CTO crossing using a steerable RF guidewire, as well as new approaches to the treatment of structural heart disease.
Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.
About Forward Looking Statements
This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.